Citadel Advisors
ATYR

Citadel Advisors’s aTyr Pharma ATYR Stock Holding History

Citadel Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Buy
249,000
+140,800
+130% +$92K ﹤0.01% 12358
2026
Q1 		$84.4K Sell
108,200
-19,000
-15% -$16K ﹤0.01% 12145
2025
Q4 		$99.6K Sell
127,200
-72,600
-36% -$59.6K ﹤0.01% 11648
2025
Q3 		$144K Buy
199,800
+9,400
+5% +$42.6K ﹤0.01% 11557
2025
Q2 		$965K Buy
190,400
+167,800
+742% +$660K ﹤0.01% 7182
2025
Q1 		$68.3K Sell
22,600
-5,200
-19% -$19K ﹤0.01% 11948
2024
Q4 		$101K Buy
27,800
+12,300
+79% +$37.2K ﹤0.01% 11472
2024
Q3 		$27.3K Buy
15,500
+15,300
+7,650% +$27.8K ﹤0.01% 12521
2024
Q2 		$312 Sell
200
-7,300
-97% -$12.7K ﹤0.01% 14034
2024
Q1 		$14.6K Buy
7,500
+6,800
+971% +$11.9K ﹤0.01% 13229
2023
Q4 		$987 Sell
700
-7,100
-91% -$9.11K ﹤0.01% 13903
2023
Q3 		$12.3K Sell
7,800
-1,900
-20% -$3.52K ﹤0.01% 12971
2023
Q2 		$21K Buy
9,700
+3,100
+47% +$6.77K ﹤0.01% 12690
2023
Q1 		$13.9K Buy
6,600
+3,700
+128% +$8.11K ﹤0.01% 13342
2022
Q4 		$6.35K Sell
2,900
-15,900
-85% -$37.5K ﹤0.01% 13926
2022
Q3 		$56K Buy
18,800
+5,300
+39% +$17.8K ﹤0.01% 11543
2022
Q2 		$38K Sell
13,500
-13,800
-51% -$49.9K ﹤0.01% 12103
2022
Q1 		$146K Buy
27,300
+12,900
+90% +$73.1K ﹤0.01% 11880
2021
Q4 		$108K Sell
14,400
-6,000
-29% -$50.1K ﹤0.01% 12641
2021
Q3 		$185K Buy
20,400
+5,900
+41% +$35.3K ﹤0.01% 12099
2021
Q2 		$71K Buy
+14,500
New +$61.8K ﹤0.01% 13159

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's ATYR Position: Q2 2026 in Review

Citadel Advisors increased its aTyr Pharma (ATYR) stake by 2,522% in Q2 2026, buying an estimated $780K and bringing the position to 1,242,067 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #8927.

Citadel Advisors first reported a position in ATYR in Q4 2015 and has held it in 26 quarters since. The position peaked at $3.71M in Q1 2024. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Citadel Advisors held 1,242,067 shares of aTyr Pharma worth $741K as of Q2 2026.
  • Citadel Advisors bought 1,194,695 aTyr Pharma shares in Q2 2026, an estimated $780K.
  • aTyr Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8927 holding.
  • Citadel Advisors first reported a position in aTyr Pharma in Q4 2015 and has held it in 26 quarters since.
  • Citadel Advisors's aTyr Pharma position peaked at $3.71M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.